Japan Digital Biomarkers Market Report 2023 to 2030

Japan Digital Biomarkers Market Analysis

$ 3999

Japan Digital Biomarkers Market was valued at $180.26 Mn in 2023 and is predicted to grow at a CAGR of 22.8% from 2023 to 2030, to $759.08 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, the aging population, and the focus on innovation. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.

ID: IN10JPDH158 CATEGORY: Digital Health GEOGRAPHY: Japan AUTHOR: Sarita Yadav

Buy Now

Japan Digital Biomarkers Market Executive Summary

Japan Digital Biomarkers Market was valued at $180.26 Mn in 2023 and is predicted to grow at a CAGR of 22.8% from 2023 to 2030, to $759.08 Mn by 2030.

Digital biomarkers are quantifiable physiological and behavioral data collected by digital devices like wearables and smartphones. They provide insights into health, including disease progression and treatment response, enabling continuous monitoring and real-time data collection. These biomarkers are used for various health conditions, such as diabetes, cardiovascular disorders, mental health issues, and neurodegenerative diseases. By tracking metrics like physical activity, heart rate, and sleep patterns, digital biomarkers help clinicians make informed decisions and support research with real-world evidence. As technology advances, their potential to transform healthcare and improve patient outcomes grows.

In Japan, over 82% of deaths are attributed to chronic diseases. During the COVID-19 pandemic, market players introduced innovative solutions, such as a cost-effective mobile app by Maastricht University (September 2022) to detect COVID-19 via voice changes.

The market therefore is driven by significant factors like the growing prevalence of chronic diseases, the aging population, and focus on innovation. However, the regulatory landscape, data privacy concerns, and limited integration with healthcare systems restrict the growth and potential of the market.

Prominent players in this field are ActiGraph LLC which specializes in wearable devices and data analytics for physical activity and sleep monitoring, contributing to clinical research through reliable digital biomarkers. AliveCor Inc. excels in portable ECG monitoring and AI-driven cardiac analysis, enhancing early diagnosis and intervention with FDA-cleared devices like KardiaMobile. Others contributors include Koneksa, and Altoida Inc. among others.

Japan Digital Biomarkers Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Growing Prevalence of Chronic Diseases: Japan faces a growing burden of chronic diseases like diabetes, heart disease, and obesity. Digital biomarkers offer valuable tools for early detection, monitoring, and management of these conditions, driving market growth.

Aging Population: As of 2022, over 29.1% of the Japanese population is aged 65 or above, highlighting Japan's rapidly aging population. This demographic shift increases the need for effective chronic disease management and preventative healthcare solutions. Digital biomarkers emerge as valuable tools in this context, offering capabilities for early detection, monitoring, and personalized treatment of chronic conditions, thereby driving market growth in Japan.

Focus on Innovation: Japan boasts a strong emphasis on technological advancement in healthcare. Government initiatives and public-private partnerships support the development and adoption of innovative solutions like digital biomarkers.

Market Restraints

Regulatory Landscape: Japan's strict and complex regulatory framework for medical devices can pose challenges for market entry. Understanding the classification process and navigating the approval process with the Pharmaceuticals and Medical Devices Agency (PMDA) can be time-consuming and resource-intensive.

Data Privacy Concerns: Data security and privacy are major concerns in Japan. Building trust with users regarding data collection, storage, and usage practices is essential for market adoption. Compliance with regulations like the Act on the Protection of Personal Information (APPI) is paramount.

Limited Integration with Healthcare Systems: Seamless integration of digital biomarker data with existing healthcare information systems in Japan is necessary for optimal utilization by healthcare professionals. Current interoperability challenges might hinder wider adoption.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape for digital biomarkers in Japan involves several key players, including the Ministry of Health, Labour and Welfare (MHLW), which oversees medical device regulation. The Pharmaceuticals and Medical Devices Agency (PMDA), a sub-agency of the MHLW, is responsible for the technical evaluation and approval of medical devices, including digital biomarkers. Additionally, the Japanese Agency for Medical Research and Development (AMED) supports healthcare technology innovation and may offer grants or participate in pilot programs for digital biomarkers. Understanding how the MHLW classifies digital biomarkers, whether as software-based or in vitro diagnostics (IVDs), is crucial for determining the appropriate regulatory pathway. Compliance with Japan’s stringent data privacy laws, such as the Act on the Protection of Personal Information (APPI), is also essential.

Regarding reimbursement, Japan's National Health Insurance (NHI) system offers the potential for coverage of innovative solutions, including digital biomarkers with demonstrated clinical value. This coverage is contingent upon meeting specific conditions. Additionally, private health insurance is prevalent in Japan, and some insurers may offer coverage for digital health solutions that integrate digital biomarkers, depending on the specific technology and insurance plan.

Competitive Landscape

Key Players

Here are some of the major key players in the Japan Digital Biomarkers Market

ActiGraph LLC
AliveCor Inc.
Koneksa
Altoida Inc.
Amgen Inc.
Biogen Inc.
Empatica Inc.
Vivo Sense
IXICO plc
Adherium Limited

1. Executive Summary
1.1 Digital Health Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Digital Health Policy in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Digital Biomarkers Market Segmentation

By Type

Wearable
Mobile-based Applications
Sensors
Others

By Clinical Practice

Diagnostic digital biomarkers
Monitoring digital biomarkers
Predictive and Prognostic digital biomarkers
Other's (Safety, Pharmacodynamics/ Response, Susceptibility)

By Therapeutic Area

Cardiovascular and metabolic disorders (CVMD)
Respiratory disorders
Psychiatric disorders
Sleep & Movement Disease
Neurological disorders
Musculoskeletal disorders
Others (Diabetes, Pain Management)

By End-Use

Healthcare companies
Healthcare Providers
Payers
Others (Patients, caregivers)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.